# US 2019/0375841 A1 · Anti-ntb-a antibodies and related compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375841 A1
- Document ID: US20190375841A1
- Status: Published application
- Kind: A1
- Application number: 16/553,525
- Filed: 2019-08-28
- Published: 2019-12-12
- Earliest claimed: 2012-12-21
- Assignees: Seattle Genetics, Inc.
- Applicants: Seattle Genetics, Inc.
- Inventors: Timothy S. Lewis; Che-Leung Law
- Web page: https://patentgrep.com/patent/US20190375841A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K 2039/505: {comprising antibodies}
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells. Further disclosed is a method of treating multiple myeloma using an anti-NTB-A antibody drug conjugate, which optionally includes an anti-NTB-A antibody as disclosed herein.

## Claims

### Claim 1

An isolated monoclonal antibody comprising VH and VL domains sharing at least 80% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the VH and VL domains share at least 90% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the VH and VL domains share at least 95% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein the VH and VL domains share at least 99% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2.

### Claim 5 (depends on 2)

The antibody of claim 2, wherein the antibody is chimeric or humanized.

### Claim 6 (depends on 1)

The antibody of claim 1, wherein the antibody is conjugated to a cytotoxic or cytostatic agent.

### Claim 7 (depends on 2)

The antibody of claim 2, wherein the antibody is conjugated to a cytotoxic or cytostatic agent.

### Claim 8 (depends on 3)

The antibody of claim 3, wherein the antibody is conjugated to a cytotoxic or cytostatic agent.

### Claim 9 (depends on 4)

The antibody of claim 4, wherein the antibody is conjugated to a cytotoxic or cytostatic agent.

### Claim 10 (depends on 5)

The antibody of claim 5, wherein the antibody is conjugated to a cytotoxic or cytostatic agent.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising:
the antibody of claim 1; and
a pharmaceutically compatible ingredient.

### Claim 12 (depends on 2)

A pharmaceutical composition comprising:
the antibody of claim 2; and
a pharmaceutically compatible ingredient.

### Claim 13 (depends on 3)

A pharmaceutical composition comprising:
the antibody of claim 3; and
a pharmaceutically compatible ingredient.

### Claim 14 (depends on 4)

A pharmaceutical composition comprising:
the antibody of claim 4; and
a pharmaceutically compatible ingredient.

### Claim 15 (depends on 5)

A pharmaceutical composition comprising:
the antibody of claim 5; and
a pharmaceutically compatible ingredient.

### Claim 16

An antibody drug conjugate comprising an antibody conjugated to a cytotoxic agent, wherein the antibody comprises VH and VL domains sharing at least 80% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2.

### Claim 17

An antibody drug conjugate comprising an antibody conjugated to a cytotoxic agent, wherein the antibody comprises VH and VL domains sharing at least 90% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2.

### Claim 18 (depends on 16)

A pharmaceutical composition comprising the antibody drug conjugate of claim 16.

### Claim 19 (depends on 17)

A pharmaceutical composition comprising the antibody drug conjugate of claim 17.